Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)156.80
  • Today's Change0.00 / 0.00%
  • Shares traded570.63k
  • 1 Year change-4.51%
  • Beta1.2186
Data delayed at least 20 minutes, as of Nov 08 2024 16:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments329352468
Total Receivables, Net142223
Total Inventory------
Prepaid expenses4.311211
Other current assets, total0.000.000.00
Total current assets347386502
Property, plant & equipment, net193744
Goodwill, net------
Intangibles, net0.910.830.99
Long term investments321261397
Note receivable - long term4.60171.29
Other long term assets0.880.010.81
Total assets694703946
LIABILITIES
Accounts payable152711
Accrued expenses292622
Notes payable/short-term debt3.702.353.92
Current portion long-term debt/capital leases3.39104.81
Other current liabilities, total0.1732184
Total current liabilities5197226
Total long term debt183443
Total debt254752
Deferred income tax522090
Minority interest(5.84)5.37(9.37)
Other liabilities, total1144.132.66
Total liabilities230160352
SHAREHOLDERS EQUITY
Common stock5.465.465.44
Additional paid-in capital290290289
Retained earnings (accumulated deficit)213274298
Treasury stock - common(45)(26)--
Unrealized gain (loss)------
Other equity, total0.180.090.47
Total equity464542594
Total liabilities & shareholders' equity694703946
Total common shares outstanding272289288
Treasury shares - common primary issue18110
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.